Douillard, J.Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzales-Larriba, J.L., Grodzki, T., Pereira, J.R., Le Groumellec, A., Lorusso, V., Clary, C., Torres, A.J., Dahabreh, J., Souquet, P.J., Astudillo, J., Fournel, P., Artal-Cortes, A., Jassem, J., Koubkova, L., His, P., Riggi, M. and Hurteloup, P. (2006) Adjuvant Vinorelbine plus Cisplatin versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial. The Lancet Oncology, 7, 719-727. http://dx.doi.org/10. 1016/S1470-2045(06)70804-X

has been cited by the following article:

• TITLE: Feasibility Study for Biweekly Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer Patients in a Japanese Population

  AUTHORS: Shuichi Tsukamoto, Koji Yamazaki, Ryo Mori, Masakazu Katsura, Hidenori Kouso, Daigo Kawano, Chie Ushijima, Sadanori Takeo

  KEYWORDS: NSCLC; Adjuvant Chemotherapy; Cisplatin and Vinorelbine; Biweekly

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.1, February 18, 2014

  ABSTRACT: Purpose: To evaluate the feasibility of biweekly administration of cisplatin and vinorelbine as adjuvant chemotherapy for patients with completely resected non-small cell lung cancer (NSCLC). Patients and Methods: This was a single-arm, single-institutional study. Patients with completely resected NSCLC (p-Stage IB-IIIA) with no previous chemotherapy or radiotherapy were eligible. Simon’s optimal two-stage design was applied. Both cisplatin (50 mg/m2) and vinorelbine (25 mg/m2) were given on days 1 and 15, every 28 days. The primary endpoint of this study was the feasibility of this combination in the four cycles of treatment. Results: Twenty patients (19 lobectomies and 1 pneumonectomy) were enrolled in this study. 10 (50%) of patients had grade 3/4 neutropenia, and 3 (15%) had grade 3/4 anemia. Severe non-hematologic toxicities were uncommon in this series. No treatment-related death was encountered. 18 (90%) patients completed the planned 4 cycles of chemotherapy. The median intensity was 24.3 (range 18.1 to 25) mg/m2/week with an average of 23.6 (21 - 25) mg/m2/week cisplatin and 12.5 (range 10 to 12.5) mg/m2/week with an average of 12.3 (10 - 12.5) mg/m2/week vinorelbine. The median relative dose intensity of cisplatin was 97.5% (range 72.5% to 100%) with an average of 94.6% (72.5% - 100%) and that of vinorelbine was 100% (range 80% to 100%) with an average of 97.8% (80% - 100%). Conclusion: This regimen is feasible in the treatment of patients with completely resected NSCLC. A phase III trial is warranted to assess the efficacy of this regimen at promoting survival and preventing recurrence.